SCHEMBL15087991

SCHEMBL15087991

Cc1cccc(C2CCC2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.48
CCR8 P51685 1/20 0.48
DRD2 P14416 7/20 0.45
HTR1A P08908 6/20 0.45
DRD4 P21917 6/20 0.45
OPRM1 P35372 1/20 0.44
OPRL1 P41146 1/20 0.44
HTR2A P28223 1/20 0.44
HTR7 P34969 1/20 0.44
MAP4K4 O95819 2/20 0.44
CNR2 P34972 2/20 0.42
ALDH1A1 P00352 3/20 0.41
CACNA1B Q00975 2/20 0.41
APBA1 Q02410 2/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
IDO1 P14902 1/20 0.41
KCNH2 Q12809 1/20 0.41
KDM5A P29375 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2757250 0.96 CCR1 (0.48) CCR1CCR8DRD2HTR1ADRD4
SCHEMBL8056158 0.94 DRD2 (0.50) CCR1CCR8DRD2HTR1ADRD4
SCHEMBL1610517 0.91 CCR1 (0.52) CCR1CCR8DRD2HTR1ADRD4
SCHEMBL30469416 0.82 HTR2C (0.47) CCR1CCR8DRD2HTR1ADRD4
SCHEMBL12093290 0.82 HTR2C (0.47) CCR1CCR8DRD2HTR1ADRD4
SCHEMBL12093289 0.82 DRD2 (0.53) CCR1CCR8DRD2HTR1ADRD4
SCHEMBL17888476 0.81 DRD2 (0.53) CCR1CCR8DRD2HTR1ADRD4
SCHEMBL171375 0.81 DRD2 (0.44) DRD2
SCHEMBL14240402 0.80 MAP4K4 (0.51) CCR1CCR8DRD2HTR1ADRD4
SCHEMBL23114442 0.79 MAP4K4 (0.50) DRD2HTR1ADRD4OPRM1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922385-A Cgrp receptor antagonists 伊莱利利公司 2018-04-17 CN disclosed
CN-107922406-A CGRP receptor antagonist 伊莱利利公司 2018-04-17 CN disclosed
US-20140088081-A1 Amino-Heterocyclic Compounds PFIZER INC. (US) 2014-03-27 US disclosed
WO-2013098373-A1 NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-07-04 WO disclosed
US-20120329777-A1 Amino-Heterocyclic Compounds PFIZER INC. 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329777-A1 Amino-Heterocyclic Compounds PDE9A, PDE2A, PDE10A CCR1 3406/4885CCR8 3883/4885DRD2 205/4885
US-20140088081-A1 Amino-Heterocyclic Compounds PDE9A, PDE2A, PDE10A CCR1 3406/4885CCR8 3883/4885DRD2 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.